

Prior Authorization Request Form Fax Back To: (866) 940-7328

Phone: (800) 310-6826

Specialty Medication Prior Authorization Cover Sheet

(This cover sheet should be submitted along with a Pharmacy Prior Authorization Medication Fax Request Form. Please refer to www.uhcprovider.com for medication fax request forms.)

Patient Information						
Patient's Name:						
Insurance ID:	Date of Birth:	Height: Weight:				
Address:		Apartment #:				
City:	State:	Zip Code:				
Phone Number:	Alternate Phone:	Sex: Male Female				
Provider Information						
Provider's Name:	Provider ID Number:					
Address:	City:	State: Zip Code:				
Suite Number:	Building Number:					
Phone Number:	Fax number:					
Provider's Specialty:						
Medication Information						
Medication:	Quantity:	ICD10 Code:				
Directions:	Diagnosis:	Refills:				
Physician Signature**:		Initial here if DAW:				
Physician Signature**: By signing above, the physician is providing the specialty pharmacy with a prescription that can be used to facilitate the dispensing and/or coordination of delivery for the requested medication.						
Medication Instructions						
Medication Instructions Has the patient been instructed on how to Self-	Administer?	☐ Yes ☐ No				
	Administer?	☐ Yes ☐ No				
Has the patient been instructed on how to Self-						
Has the patient been instructed on how to Self- Is this medication a New Start ?	Initiation Date: / /	☐ Yes ☐ No				
Has the patient been instructed on how to Self- Is this medication a New Start ? If continuation please provide the following:	Initiation Date: / / sponse to current therapy? ation that would pertain to su	☐ Yes ☐ No Date of Last Dose: / / ☐ Yes ☐ No pport stated diagnosis.				
Has the patient been instructed on how to Self- Is this medication a New Start? If continuation please provide the following: Is there documentation of positive clinical res **Please attach any pertinent clinical informational clinical information may be needed.	Initiation Date: / / sponse to current therapy? ation that would pertain to su	☐ Yes ☐ No Date of Last Dose: / / ☐ Yes ☐ No pport stated diagnosis.				
Has the patient been instructed on how to Self- Is this medication a New Start? If continuation please provide the following: Is there documentation of positive clinical reserved: **Please attach any pertinent clinical informational clinical information may be needed previously tried and failed.	Initiation Date: / / sponse to current therapy? ation that would pertain to sued depending on your patient stan Signature" above and comformation"	☐ Yes ☐ No Date of Last Dose: / / ☐ Yes ☐ No pport stated diagnosis. s plan, including medication(s) plete				
Has the patient been instructed on how to Self- Is this medication a New Start? If continuation please provide the following: Is there documentation of positive clinical res **Please attach any pertinent clinical inform Additional clinical information may be needed previously tried and failed. Delivery Instructions Note: Delivery coordination requires a "Physical "Provider Information" and "Patient Information"	Initiation Date: / / sponse to current therapy? ation that would pertain to sued depending on your patient sian Signature" above and comformation" ided free of charge to the patient	☐ Yes ☐ No Date of Last Dose: / / ☐ Yes ☐ No pport stated diagnosis. s plan, including medication(s) plete Int at the time of delivery				



Ibrance - Washington

PRIOR AUTHORIZATION REQUEST FORM

Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826.

This form contains multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

Section A – Member Information						
First Name:	Last Name:			Member ID:		
Address:						
City:	State:	State:			ZIP Code:	
Phone:	DOB:		,	Allergies:		
Primary Insurance Information:						
Is the requested medication □ New of	or □ Continua	ation of Therapy? If	continuation, list	start date: _		
Is this patient currently hospitalized	l? □ Yes □ N	lo If recently discha	arged, list discha	arge date:		
Section B - Provider Information						
First Name:		Last Name:			M.D./D.O.	
Address:		City:		State:	ZIP code:	
Phone: Fax:		NPI#:	1	Specialty:		
Office Contact Name / Fax attention to):		•			
Section C - Medical Information				Otro martha		
Medication:				Strength:		
Directions for use:				Quantity:		
Diagnosis (Please be specific & provi	de as much in	nformation as possible	e):	ICD-10 CC	DDE:	
<u> </u>						
Is this member pregnant? Yes		es, what is this men	nber's due date?			
Section D - Previous Medication Tri	ials				son for failure /	
		es, what is this men Directions	nber's due date? Dates of Thei	rapy Rea	son for failure /	
Section D - Previous Medication Tri	ials			rapy Rea		
Section D - Previous Medication Tri	ials			rapy Rea		
Section D - Previous Medication Tri	ials			rapy Rea		
Section D - Previous Medication Tri	ials			rapy Rea		
Section D – Previous Medication Tri Medications	als Strength	Directions	Dates of The	rapy Rea dis	scontinuation	
Section D – Previous Medication Tri Medications Section E – Additional information ar	ials Strength	Directions on of why preferred n	Dates of The	rapy Rea dis	che patient's needs:	
Section D – Previous Medication Tri Medications	ials Strength	Directions on of why preferred n	Dates of The	rapy Rea dis	che patient's needs:	
Section D – Previous Medication Tri Medications Section E – Additional information ar	ials Strength	Directions on of why preferred n	Dates of The	rapy Rea dis	scontinuation	
Section D – Previous Medication Tri Medications Section E – Additional information ar	ials Strength	Directions on of why preferred n	Dates of The	rapy Rea dis	scontinuation	
Section D – Previous Medication Tri Medications Section E – Additional information ar	ials Strength	Directions on of why preferred n	Dates of The	rapy Rea dis	scontinuation	
Section D – Previous Medication Tri Medications Section E – Additional information ar	ials Strength	Directions on of why preferred n	Dates of The	rapy Rea dis	scontinuation	
Section D – Previous Medication Tri Medications Section E – Additional information ar	ials Strength	Directions on of why preferred n	Dates of The	rapy Rea dis	che patient's needs:	
Section D – Previous Medication Tri Medications Section E – Additional information ar	ials Strength	Directions on of why preferred n	Dates of The	rapy Rea dis	che patient's needs:	
Section D – Previous Medication Tri Medications Section E – Additional information ar	ials Strength	Directions on of why preferred n	Dates of The	rapy Rea dis	scontinuation	



Physician Signature: _____

Ibrance - Washington

PRIOR AUTHORIZATION REQUEST FORM

Date:_

Member Fi	rst name:	Member Last name:	Member DOB:				
Clinical and Drug Specific Information							
ALL REQUESTS							
□ Yes □ No	Which of the following diagnoses does the patient have: (If yes, check which applies) □ Advanced, recurrent or metastatic breast cancer □ Unresectable well differentiated/dedifferentiated Liposarcoma (WD-DDLS) for Retroperitoneal Sarcomas						
□ Yes □ No	Is the medication being requested for a use supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium? If yes, list supported use:						
□ Yes □ No	Is the disease hormone-receptor (HR)-positive?						
□ Yes □ No	Is the disease human epidermal growth factor receptor 2 (HER2) – negative?						
□ Yes □ No	Is Ibrance being used in combination with an aromatase inhibitor (e.g. anastrozole, letrozole, exemestane)?						
□ Yes □ No	Is Ibrance being used in combination with Faslodex?						
CONTINUATION OF THERAPY							
□ Yes □ No	Does the patient show evidence of progressive disease while on Ibrance therapy?						
□ Yes □ No	Is there documentation of positive clinical response to Ibrance therapy? If yes, list response:						

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.